Medline Inc. MDLN
No target with a reported result yet
Releases of the last 3 yearsThe numbers MDLN said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| EBITDA (company-defined) Fiscal 2026 |
Given $3.50B to $3.60B release Feb 25, 2026
Lowered $3.30B to $3.40B release Nov 4, 2026
|
– | No standard number | |
The company's wordsFor full year 2026, the Company expects Organic Sales 4 growth of 8% to 9% and Adjusted EBITDA 4 of $3.5 to $3.6 billion. release Feb 25, 2026 The Company is raising its full year 2026 outlook for Organic Sales 2 growth to 10.0% to 10.5%, compared to its previous outlook of 9.0% to 10.0%, and reaffirming its Adjusted EBITDA 2 outlook of $3.3 billion to $3.4 billion. release Nov 4, 2026 | ||||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (4 releases since 2026-02-25), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MDLN/export.csv") into a cell.